EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cellular Senescence, Inflammaging and Cardiovascular Disease

Lukas Zanders iD, Denada Arifaj iD, Julian U G Wagner iD, Stefanie Dimmeler iD

Immunological Reviews · 2026-01 · 337 (1)

DOI: 10.1111/imr.70084 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 16.01.2026. Verfasst von Lukas Zanders und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular Regeneration, Frankfurt, Germany. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Cellular Senescence, Inflammation, Aging. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsches Zentrum für Herz-Kreislaufforschung, H2020 European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aging is the most important yet unmodifiable risk factor for cardiovascular disease (CVD). As a result, targeting cardiovascular aging has emerged as a promising strategy to promote long‐term cardiovascular health. This review summarizes current knowledge on the effects of aging within the cardiovascular system as well as systemic processes that modulate them. We highlight the roles of cellular senescence and the senescence‐associated secretory phenotype (SASP), emphasizing their heterogeneous contributions to chronic low‐grade inflammation and tissue remodeling—collectively termed inflammaging. Advances in biomarkers, animal models, and systems biology approaches have deepened our understanding of the interplay between senescence, inflammaging, and cardiovascular dysfunction, including the pivotal role of macrophages in senescent cell clearance. Therapeutic strategies are diverse, ranging from senolytic approaches designed to selectively eliminate senescent cells, to SASP modulation, and interventions targeting chronic inflammation and metabolic dysregulation. Of particular interest, drugs already in clinical use—such as metformin and other anti‐diabetic agents—show beneficial effects on aging‐related pathways, suggesting that their cardiovascular protection may in part reflect anti‐aging properties. Despite these advances, therapies directly targeting senescence and inflammaging to reduce the global burden of CVD remain an urgent unmet need.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesCellular SenescenceInflammationAgingHumansAnimalsSenescence-Associated Secretory Phenotype

Stichwörter der Autor:innen

cardiovascular diseasecellular senescenceheart failureinflammagingsenolyticsenomorphic

Autor:innen und Institutionen

  • Institute of Cardiovascular Regeneration, Frankfurt, Germany.
  • German Center for Cardiovascular Research, Partner Site Rhein/Main, Frankfurt, Germany.
  • Clinic for Cardiology, University Hospital Frankfurt, Frankfurt, Germany.
  • Cardiopulmonary Institute, Giessen, Germany.

ORCID-Profile: Lukas Zanders, Denada Arifaj, Julian U G Wagner, Stefanie Dimmeler

Förderung

  • Deutsche Forschungsgemeinschaft
  • Deutsches Zentrum für Herz-Kreislaufforschung
  • H2020 European Research Council

Zitieren

APA

Zanders, L., Arifaj, D., Wagner, J. U. G., & Dimmeler, S. (2026). Cellular Senescence, Inflammaging and Cardiovascular Disease. Immunological Reviews, 337(1). https://doi.org/10.1111/imr.70084

Vancouver

Zanders L, Arifaj D, Wagner JUG, Dimmeler S. Cellular Senescence, Inflammaging and Cardiovascular Disease. Immunological Reviews. 2026;337(1). doi:10.1111/imr.70084

BibTeX
@article{Zanders2026,
  author = {Zanders, Lukas and Arifaj, Denada and Wagner, Julian U G and Dimmeler, Stefanie},
  title = {Cellular Senescence, Inflammaging and Cardiovascular Disease},
  journal = {Immunological Reviews},
  year = {2026},
  volume = {337},
  number = {1},
  doi = {10.1111/imr.70084}
}
Kostenlos starten →